Anavex Life Sciences (NASDAQ:AVXL) reported third fiscal quarter 2026 results and provided updates on blarcamesine development programs targeting Alzheimer’s disease, Rett syndrome, and Fragile X syndrome.
Vyome Holdings (NASDAQ:HIND) reported second-quarter 2026 results and provided a corporate update, highlighting progress on VT-1953, its lead program for symptoms associated with malignant fungating wounds.
OrthoPediatrics (NASDAQ:KIDS) announced the full commercial launch of its 3P Pediatric Plating Platform Hip System in the United States after a limited launch phase that included more than 350 surgical implantations.
BioCryst (NASDAQ:BCRX) announced that Japan’s Ministry of Health, Labor and Welfare approved once-daily ORLADEYO (berotralstat) as a preventive treatment for pediatric hereditary angioedema (HAE) patients aged 2 to under 12 years.
Sagimet Biosciences (NASDAQ:SGMT) reported progress on its AURORA U.S. Phase 3 clinical trial evaluating denifanstat, a FASN inhibitor being developed for moderate to severe acne.
Beyond Air (NASDAQ:XAIR) entered a definitive agreement for UNIVO Pharmaceutical Industries to acquire control of NeuroNOS Israel, a neurology-focused biopharmaceutical company in which Beyond Air owns approximately 58% of fully diluted shares.
Bitcoin (CRYPTO:BTC) rallied approximately 25% last week, briefly breaking above US$80,000, with the weekly Relative Strength Index rising to 58.3 — its highest reading since Bitcoin's all-time high of US$126,200 was recorded in October 2025.
The Bank of Nova Scotia (NYSE:BNS) reported fiscal third-quarter 2026 net income of C$2.95 billion, up from C$2.53 billion a year earlier, with higher revenue and earnings growth across business segments.
Lotus Technology (NASDAQ:LOT) completed the acquisition of 100% of the equity interests in Lotus Advance Technologies Sdn Bhd, known as Lotus UK, bringing its British sports car operations and engineering capabilities under a single corporate structure.
McKesson (NYSE:MCK) agreed to acquire Precision Medicine Group for approximately $2.25 billion, adding clinical research and biopharma commercialization services to its oncology and multispecialty operations.
GET YOUR GRAFA EDGE NOW
Sign up free to unlock this feature
We'll switch on a 30-day Edge trial as a welcome gift
